Cargando…

Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects

BACKGROUND: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). METHODS: Patients treated with SRS or SRT for brain-only NSCLC oligom...

Descripción completa

Detalles Bibliográficos
Autores principales: Niibe, Yuzuru, Nishimura, Tetsuo, Inoue, Tetsuya, Karasawa, Katsuyuki, Shioyama, Yoshiyuki, Jingu, Keiichi, Shirato, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992231/
https://www.ncbi.nlm.nih.gov/pubmed/27542716
http://dx.doi.org/10.1186/s12885-016-2680-8
_version_ 1782448979538083840
author Niibe, Yuzuru
Nishimura, Tetsuo
Inoue, Tetsuya
Karasawa, Katsuyuki
Shioyama, Yoshiyuki
Jingu, Keiichi
Shirato, Hiroki
author_facet Niibe, Yuzuru
Nishimura, Tetsuo
Inoue, Tetsuya
Karasawa, Katsuyuki
Shioyama, Yoshiyuki
Jingu, Keiichi
Shirato, Hiroki
author_sort Niibe, Yuzuru
collection PubMed
description BACKGROUND: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). METHODS: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following: 1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70. RESULTS: The median overall survival (OS) of all 61 patients was 26 months (95 % CI: 17.5–34.5 months). The 2-year and 5-year overall survival rates were 60.7 and 15.7 %, respectively. Stratified by oligostatus, the sync-oligometastases group achieved a median OS of 18 months (95 % CI: 14.8–21.1 months) and a 5-year OS of 0 %, while the oligo-recurrence group achieved a median OS of 41 months (95 % CI: 27.8–54.2 months) and a 5-year OS of 18.6 %. On multivariate analysis, oligo-recurrence was the only significant independent factor related to a favorable prognosis (hazard ratio: 0.253 (95 % CI: 0.082–0.043) (p = 0.025). CONCLUSIONS: The presence of oligo-recurrence can predict a favorable prognosis of brain-only oligometastases in patients with NSCLC treated with SRS or SRT.
format Online
Article
Text
id pubmed-4992231
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49922312016-08-21 Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects Niibe, Yuzuru Nishimura, Tetsuo Inoue, Tetsuya Karasawa, Katsuyuki Shioyama, Yoshiyuki Jingu, Keiichi Shirato, Hiroki BMC Cancer Research Article BACKGROUND: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). METHODS: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following: 1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70. RESULTS: The median overall survival (OS) of all 61 patients was 26 months (95 % CI: 17.5–34.5 months). The 2-year and 5-year overall survival rates were 60.7 and 15.7 %, respectively. Stratified by oligostatus, the sync-oligometastases group achieved a median OS of 18 months (95 % CI: 14.8–21.1 months) and a 5-year OS of 0 %, while the oligo-recurrence group achieved a median OS of 41 months (95 % CI: 27.8–54.2 months) and a 5-year OS of 18.6 %. On multivariate analysis, oligo-recurrence was the only significant independent factor related to a favorable prognosis (hazard ratio: 0.253 (95 % CI: 0.082–0.043) (p = 0.025). CONCLUSIONS: The presence of oligo-recurrence can predict a favorable prognosis of brain-only oligometastases in patients with NSCLC treated with SRS or SRT. BioMed Central 2016-08-19 /pmc/articles/PMC4992231/ /pubmed/27542716 http://dx.doi.org/10.1186/s12885-016-2680-8 Text en © Niibe et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Niibe, Yuzuru
Nishimura, Tetsuo
Inoue, Tetsuya
Karasawa, Katsuyuki
Shioyama, Yoshiyuki
Jingu, Keiichi
Shirato, Hiroki
Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
title Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
title_full Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
title_fullStr Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
title_full_unstemmed Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
title_short Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
title_sort oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992231/
https://www.ncbi.nlm.nih.gov/pubmed/27542716
http://dx.doi.org/10.1186/s12885-016-2680-8
work_keys_str_mv AT niibeyuzuru oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects
AT nishimuratetsuo oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects
AT inouetetsuya oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects
AT karasawakatsuyuki oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects
AT shioyamayoshiyuki oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects
AT jingukeiichi oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects
AT shiratohiroki oligorecurrencepredictsfavorableprognosisofbrainonlyoligometastasesinpatientswithnonsmallcelllungcancertreatedwithstereotacticradiosurgeryorstereotacticradiotherapyamultiinstitutionalstudyof61subjects